Logo image
The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis
Journal article   Peer reviewed

The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis

Anjuli S. Nayak, Mark H. Ellis, Gary N. Gross, Louis M. Mendelson, Eric J. Schenkel, Bobby Q. Lanier, Brandon Simpson, Mary Ellen Mullin, Joseph A. Smith and Jesse A Smith
Journal of allergy and clinical immunology, v 101(2), pp 157-162
1998
PMID: 9500747

Abstract

adrenocortical function allergic rhinitis aqueous nasal spray clinical trial corticosteroids hay fever pediatric pharmacokinetics Triamcinolone acetonide
Background: Suppression of adrenocortical function, a risk associated with oral corticosteroids, is minimized with intranasal corticosteroids. Triamcinolone acetonide (TAA) aqueous nasal spray, at therapeutic doses, has no measurable effect on adrenocortical function in adults with allergic rhinitis. Objective: This double-blind, placebo-controlled study compared the effect of once-daily TAA aqueous nasal spray (220 or 440 μg) with placebo on adrenocortical function after 6 weeks of treatment in pediatric (children 6 to 12 years of age) patients with allergic rhinitis. The pharmacokinetic profile of TAA was examined after once-daily intranasal administration of TAA aqueous nasal spray 440 μg for 6 weeks. Methods: Eighty children received TAA aqueous nasal spray 220 μg or 440 μg or placebo for 6 weeks. Adrenocortical function was assessed by analyzing plasma cortisol levels before stimulation (0 hour) and at 30 and 60 minutes after a rapid 1-hour intravenous cosyntropin stimulation test performed before treatment and after 6 weeks of treatment. Samples for pharmacokinetic evaluation were collected from 19 patients at baseline (0 hour) and at 0.5, 1, 1.5, and 6 hours after the final dose of study medication. Results: After 6 weeks, no significant effects on adrenocortical function were observed at 30 or 60 minutes after cosyntropin stimulation with either dose of TAA aqueous nasal spray. TAA concentrations in plasma showed rapid elimination of the drug, with little or no accumulation. Conclusions: TAA aqueous nasal spray (220 or 440 μg/day) has no measurable effect on adrenocortical function in pediatric patients with allergic rhinitis. Pharmacokinetic parameters after 440 μg/day of TAA aqueous nasal spray indicate a rapid decline of plasma drug levels, with little or no systemic accumulation of study drug. (J Allergy Clin Immunol 1998;101:157-62.)

Metrics

10 Record Views
72 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Allergy
Immunology
Logo image